In a nutshell This study investigated the optimal doses of hypofractionated stereotactic radiation therapy (HSRT) for patients with brain metastases (BM). The data showed that a HSRT dose of 30 Gy or higher delivered in 5 daily fractions was safe and effective in these patients. Some background Stereotactic radiosurgery (SRS) is commonly used in...
Read More
In a nutshell This study evaluated the effectiveness of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) first-line treatment and performance status in older patients with EGFR-mutant non-small-cell lung cancer (NSCLC). The data showed that older patients with EGFR-mutated NSCLC who received EGFR-TKI first-line treatment with a...
Read More
In a nutshell This study evaluated the long-term outcomes of stereotactic ablative radiation therapy (SABR) and video-assisted thoracic surgery (VATS) for the treatment of patients with early-stage non-small cell lung cancer (NSCLC). The data showed that both SABR and VATS led to similar long-term survival outcomes. Some background...
Read More
In a nutshell This study evaluated the effectiveness and safety of trastuzumab deruxtecan (Enhertu) in patients with previously untreated metastatic HER2-mutant non-small-cell lung cancer (NSCLC). The data showed that trastuzumab deruxtecan was safe and showed strong anticancer activity in these patients. Some background NSCLC is the most common form...
Read More
In a nutshell This study compared the effectiveness and safety outcomes of nivolumab (N; Opdivo) plus ipilimumab (I; Yervoy) with chemotherapy versus pembrolizumab (Pem; Keytruda) plus chemotherapy as first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC). The data showed that N-I plus chemotherapy provided similar overall...
Read More
In a nutshell This study compared the effectiveness and safety outcomes of single and double immune checkpoint inhibitors (ICI)-based treatments in patients with advanced non-small-cell lung cancer (NSCLC). The data showed that the effectiveness and safety of both single and double ICI-based treatments were similar and higher...
Read More
In a nutshell This study evaluated the benefits of postoperative radiotherapy (PORT; radiation after surgery) in patients with resectable stage III-N2 non-small-cell lung cancer (NSCLC). The data showed that PORT significantly increased survival without disease progression and reduced the risk of cancer relapse for these patients. Some background...
Read More
In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT). Some background Immunotherapy is a type of cancer treatment that makes use of the immune...
Read More
In a nutshell This study evaluated whether patients with non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) therapy after surgery. The data showed that EGFR-TKI therapy after surgery significantly improved survival without disease progression in...
Read More
In a nutshell This study looked at the use of osimertinib (Tagrisso) for the treatment of EGFR-mutant advanced non-small-cell lung cancer (NSCLC) in a real-world practice. It found that osimertinib was confirmed to improve survival without cancer progressing, while the occurrence of blood clots was more common in a real-world...
Read More
In a nutshell This study evaluated the effectiveness and safety of combining cranial radiotherapy (CRT; radiotherapy tot the head) with and without anlotinib (AL3818) for the treatment of patients with non-small cell lung cancer (NSCLC) and brain metastases (BM). The data showed that anlotinib plus CRT significantly improved survival without brain...
Read More
In a nutshell This study evaluated the effect of brain metastases (BMs) status on immunotherapy effectiveness in patients with advanced lung cancer (LC). The data showed that the effectiveness of immunotherapy was similar in patients with or without BMs. Some background In 20-40% of patients with advanced LC, cancer spreads from the lung to the brain...
Read More
